Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1997016172) CONTROLLED RELEASE FORMULATION (ALBUTEROL)
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/016172 International Application No.: PCT/US1996/017991
Publication Date: 09.05.1997 International Filing Date: 04.11.1996
IPC:
A61K 9/20 (2006.01) ,A61K 9/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
28
Dragees; Coated pills or tablets
Applicants:
EDWARD MENDELL CO., INC. [US/US]; 2981 Route 22 Patterson, NY 12563, US
Inventors:
BAICHWAL, Anand, R.; US
McCALL, Troy, W.; US
Agent:
RASKIN, Martin, G. ; Steinberg, Raskin & Davidson, P.C. 1140 Avenue of the Americas New York, NY 10036, US
Priority Data:
08/553,00803.11.1995US
Title (EN) CONTROLLED RELEASE FORMULATION (ALBUTEROL)
(FR) FORMULATION A LIBERATION CONTROLEE (ALBUTEROL)
Abstract:
(EN) A sustained release pharmaceutical formulation and methods of making and using the same are provided. The sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional hydrophobic material and/or hydrophobic coating, and a medicament for sustained oral administration.
(FR) La présente invention concerne une formulation pharmaceutique à libération constante. L'invention concerne également les procédés de fabrication et d'utilisation de cette formulation. La formulation pharmaceutique à libération constante est constituée d'un excipient pour libération constante incluant un gélifiant, un diluant pharmaceutique inerte, éventuellement un matériau hydrophobe et/ou un enrobage hydrophobe, et d'un médicament à libération constante s'administrant par voie orale.
Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN
African Regional Intellectual Property Organization (ARIPO) (KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
KR1020000018064EP0804166ES2366278JPH10507210 CA2208230KR1002640240000*
AU1996077253DK0804166IN1955/MAS/1996